Epidermal Growth Factor Receptor Mutations and Their Prognostic Value with Carcinoembryonic Antigen in Pathological T1 Lung Adenocarcinoma
Table 1
Clinical and pathologic features of patients with lung adenocarcinoma with a maximum diameter of 3.0 cm or less and stratified by presence and absence of EGFR mutations. Where appropriate, data are n (%).
Characteristics
All ()
EGFR mutated ()
EGFR wild type ()
Age, mean y (range)
57.0 ± 10.0 (26–84)
60.5 ± 10.0 (28–84)
55.0 ± 10.5 (26–77)
<0.001a
Sex
Male
175 (30.5)
69 (39.4)
106 (60.6)
0.780b
Female
398 (69.5)
151 (37.9)
247 (62.1)
Smoking
Nonsmoker
468 (81.7)
184 (39.3)
284 (60.7)
0.375b
Current/former
105 (18.3)
36 (34.3)
69 (65.7)
CEA
<2.12 IU/mL
378 (66.0)
133 (35.2)
245 (64.8)
0.030b
≥2.12 IU/mL
195 (34.0)
87 (44.6)
108 (55.4)
Type of surgery
Lobectomy
392 (68.4)
156 (39.8)
236 (60.2)
0.356b
Limited
181 (31.6)
64 (35.4)
117 (64.6)
Tumour size
pT1a
305 (53.2)
76 (24.9)
229 (75.1)
<0.001b
pT1b
197 (34.4)
103 (52.3)
94 (47.7)
pT1c
71 (12.4)
41 (57.7)
30 (42.3)
Histology
AIS
170 (29.7)
34 (20.0)
136 (80.0)
<0.001b
MIA
167 (29.1)
57 (34.1)
110 (65.9)
IAC
236 (41.2)
129 (54.7)
107 (45.3)
IAC subtype ()
Lepidic
53 (22.5)
30 (56.6)
23 (43.4)
0.041c
Acinar
65 (27.5)
40 (62.5)
25 (37.5)
Papillary
105 (44.5)
57 (54.3)
48 (45.7)
Solid
9 (3.8)
2 (22.2)
7 (77.8)
Mucinous variant
4 (1.7)
0
4 (100.0)
Pleural invasion
No
528 (92.1)
195 (36.9)
333 (63.1)
0.016b
Yes
45 (7.9)
25 (55.6)
20 (44.4)
Lymph nodes
pN0
546 (95.3)
204 (37.4)
342 (62.6)
0.026b
pN1 or 2
27 (4.7)
16 (59.3)
11 (40.7)
Pathological stage
0
170 (29.7)
34 (20.0)
136 (80.0)
<0.001c
IA
339 (59.2)
149 (44.0)
190 (56.0)
IB
37 (6.4)
21 (56.8)
16 (43.2)
IIA, IIB, IIIA
27 (4.7)
16 (59.3)
11 (40.7)
CEA: carcinoembryonic antigen; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IAC: invasive adenocarcinoma. by at-test, bPearson’s chi-squared test, and cFisher’s exact test.
